Sp987
MAKING AI LESS “ARTIFICIAL”: PRACTICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN ENDOSCOPY AND MOTILITY
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Technology is pervasive and its role in healthcare continues to grow. This session will give attendees hand on tips to consider how three key technological innovations are transforming GI care: artificial intelligence, social media, electronic medical records and new endoscopic technology. Thought leaders in each of these areas will provide practical approaches in each of these areas for the fellow, clinician, educator and practice leader across education, care delivery and care transformation. Advance practice providers will also benefit from these sessions and lend an important perspective to the discussion.
Technology is pervasive and its role in healthcare continues to grow. This session will give attendees hand on tips to consider how three key technological innovations are transforming GI care: artificial intelligence, social media, electronic medical records and new endoscopic technology. Thought leaders in each of these areas will provide practical approaches in each of these areas for the fellow, clinician, educator and practice leader across education, care delivery and care transformation. Advance practice providers will also benefit from these sessions and lend an important perspective to the discussion.
Presenter
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
